Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 8(2023), 1 vom: 19. März, Seite 118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guan, Xiuwen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6804DJ8Z9U |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 12.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-023-01322-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354408119 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354408119 | ||
| 003 | DE-627 | ||
| 005 | 20231226062146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-023-01322-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354408119 | ||
| 035 | |a (NLM)36935426 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guan, Xiuwen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 650 | 7 | |a pyrotinib |2 NLM | |
| 650 | 7 | |a Acrylamides |2 NLM | |
| 650 | 7 | |a Aminoquinolines |2 NLM | |
| 700 | 1 | |a Ma, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiayu |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Binghe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 8(2023), 1 vom: 19. März, Seite 118 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |g day:19 |g month:03 |g pages:118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-023-01322-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 |b 19 |c 03 |h 118 | ||